Bellevue Group’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-208,745
| Closed | -$6.63M | – | 171 |
|
|
2023
Q3 | $6.63M | Sell |
208,745
-32
| -0% | -$1.02K | 0.11% | 96 |
|
|
2023
Q2 | $17.2M | Buy |
208,777
+36,792
| +21% | +$3.03M | 0.24% | 83 |
|
|
2023
Q1 | $17.7M | Buy |
171,985
+681
| +0.4% | +$70K | 0.26% | 84 |
|
|
2022
Q4 | $25.1M | Buy |
171,304
+8,000
| +5% | +$1.17M | 0.33% | 77 |
|
|
2022
Q3 | $27.6M | Buy |
163,304
+7,496
| +5% | +$1.27M | 0.4% | 67 |
|
|
2022
Q2 | $18M | Sell |
155,808
-2,352
| -1% | -$272K | 0.25% | 90 |
|
|
2022
Q1 | $15.8M | Sell |
158,160
-8,400
| -5% | -$838K | 0.18% | 98 |
|
|
2021
Q4 | $25.9M | Sell |
166,560
-3,880
| -2% | -$603K | 0.27% | 93 |
|
|
2021
Q3 | $40.2M | Buy |
170,440
+52,800
| +45% | +$12.4M | 0.41% | 78 |
|
|
2021
Q2 | $39.9M | Buy |
117,640
+3,640
| +3% | +$1.24M | 0.39% | 79 |
|
|
2021
Q1 | $46.1M | Buy |
114,000
+36,960
| +48% | +$15M | 0.49% | 66 |
|
|
2020
Q4 | $51.3M | Buy |
+77,040
| New | +$51.3M | 0.59% | 52 |
|